Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. - Wikidata - awgldk - TriplyDB

Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults.

Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults.

http://www.wikidata.org/entity/Q34158675

about

Pharmacotherapies for cannabis dependence Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents Newer generation antidepressants for depressive disorders in children and adolescents State of the art treatments for cannabis dependence Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review TREATMENT TRIAL AND LONG-TERM FOLLOW-UP EVALUATION AMONG COMORBID YOUTH WITH MAJOR DEPRESSION AND A CANNABIS USE DISORDER.LONGER-TERM EFFECTIVENESS OF CBT IN TREATMENT OF COMORBID AUD/MDD ADOLESCENTS.The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): study protocol for a randomised control trial.Evaluation of cognitive behavioral therapy/motivational enhancement therapy (CBT/MET) in a treatment trial of comorbid MDD/AUD adolescents Pharmacological treatment of cannabis dependence.Paradoxical Decrease in Striatal Activation on an fMRI Reward Task Following Treatment in Youth with Co-morbid Cannabis Dependence/Major Depression.Major depression and treatment response in adolescents with ADHD and substance use disorder.Cannabis and psychopathology: The meandering journey of the last decade Sex differences in cannabis withdrawal symptoms among treatment-seeking cannabis users.A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders Motivational Interviewing to Reduce Substance Use in Adolescents with Psychiatric Comorbidity Treatment of Cannabis Use Disorder: Current Science and Future Outlook.Vilazodone for cannabis dependence: A randomized, controlled pilot trial.Emerging Pharmacologic Treatments for Adolescent Substance Use: Challenges and New Directions.Evidence-based Treatment Options in Cannabis Dependency.Pharmacotherapy for Substance Use Disorders in Youths.A Review of the Literature of Mirtazapine in Co-Occurring Depression and an Alcohol Use Disorder.Novel Pharmacologic Approaches to Treating Cannabis Use Disorder.Efficacy and tolerability of antidepressants in the treatment of adolescents and young adults with depression and substance use disorders: a systematic review and meta-analysis.Pharmacologic management of comorbid post-traumatic stress disorder and addictions.Treating Mental Health and Substance Use Disorders in Adolescents: What Is on the Menu?Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial.Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study.The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal.Commentary on Zhou et al. (2015): Treating psychiatric comorbidity in adolescents--an important problem.Psychosocial and pharmacological interventions for the treatment of cannabis use disorder.Topiramate and motivational enhancement therapy for cannabis use among youth: a randomized placebo-controlled pilot study.

P2860

Q24187250-FB482E30-8B75-41E6-B156-97BCEA8C280A Q24187748-87B21669-2205-40B4-820B-C12F6C7238AC Q24202873-8CB6B8B9-F2A9-4D68-8984-0AF72DE82B93 Q24607810-78F8F898-ECA4-4BB5-9DD7-3021F1C704F4 Q26746192-95E87D40-6522-4038-8E3C-1C4C1422FCF8 Q34357284-EE8B0BF6-3032-4FDE-BFC2-50DA025F9FB5 Q34372579-C1840CA7-2AF3-4EA1-B5FC-EE2DF1E9FEBB Q34504812-C07D611F-7850-460C-8AD8-6C1A7074B3BA Q34981271-EF6ACE42-6D7C-4257-A014-66E1236AB9EE Q35210350-B64DFBFD-C225-4050-A365-285CBB922F62 Q35493939-45613C82-D8B4-4C3F-BA22-B922D30EB4D4 Q35633131-E820E719-5DB4-471A-8BDF-BB02184F1A03 Q35716762-927CD8E0-93AB-4D43-A96C-BA670AAD30CF Q36562406-A3FB240F-DA43-4D7D-9A1D-10394FDF1710 Q36794579-AD5D13F8-061A-428B-83EB-6D79AAB92B04 Q36798092-D7F0D813-92EF-40E4-85DF-D7E8B92E3BCF Q36936298-6E857E37-1CDC-4DB7-8927-E0CFA8815B50 Q37077380-3AEE26E6-C706-4728-A3D6-51653181432F Q37200944-6C9ECDDB-6079-47C9-85BB-2C38E1C28B9A Q37396986-EC1541F3-8CF8-432A-83DC-8F96BEDFC67A Q37574339-1B5725A3-7CC6-4ADF-B641-29690828BB74 Q37738677-7F86B0DE-B2CB-46D8-B4FD-B7B1940453D5 Q38222436-A4982358-7DD8-4F23-95FD-81320C1D3871 Q38237466-1C9E3956-F343-4C88-B243-D2682BFE1D48 Q38640003-CBFF6CE5-19BA-4932-9814-370C404AEC9A Q38766157-B3C5F17D-FD02-487B-8786-816B877B6D03 Q42376367-52E8473B-B4DC-42F9-B770-AD0DC4E514B4 Q47817946-E25F2AF8-5ADA-4B70-BC4A-1803E067DA14 Q47963315-61D582C3-C2AD-4E8E-819A-DE91F79E7968 Q48151066-FA11BFC5-517C-44B8-96C2-62C5E492A004 Q52316000-BE1926EB-905D-4869-BD02-3D96AE4A3062 Q54976153-5A56A50F-2773-4B41-B325-16B8FDEBCAD7

P2860

Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults.

http://www.wikidata.org/entity/Q34158675

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults.

@ast

Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults.

@en

Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults.

@nl

type

label

Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults.

@ast

Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults.

@en

Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults.

@nl

prefLabel

Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults.

@ast

Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults.

@en

Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults.

@nl

P1433

Q34158675-5D3540FD-890A-43C9-8F13-55925D2835AD

P1476

Q34158675-3B584E14-9440-4E3A-81ED-53E8CCACB082

P2093

Q34158675-0A43BE99-7D7E-488B-8FE1-9FAE54400FA2

Q34158675-17E1E7E4-3E05-463B-8D7C-E7E854F1FDC0

Q34158675-647619A5-C9DC-48B3-8FA0-3C5D184BB93B

Q34158675-699B3092-A59B-44CE-9328-D07C7EFAB8C0

Q34158675-91F2ECEB-CB61-4060-964B-CF55E2A9BBAD

Q34158675-BC4EB3DB-5C27-473F-AFBA-A42D96766C51

Q34158675-F3D8A51E-AE1E-4EB9-816D-B3180D7E6AEF

P2860

Q34158675-08601F7A-84E3-40DC-B341-7961F7ABF630

Q34158675-1285294C-BD9C-4A79-B7C6-533D431545D4

Q34158675-1716AF90-0A54-4355-86DA-967CA5F83EE1

Q34158675-1A248509-DF99-47B9-AAF5-9190C8A8FDBF

Q34158675-1A483964-7A69-4F18-A0D9-C548FE6A9181

Q34158675-1B9BDB79-6011-4024-96F1-9480D01D314F

Q34158675-1E35EB8D-34A6-4BA8-9111-6EDD791BFB32

Q34158675-237D9923-5103-48B9-87C2-8AB9E2445468

Q34158675-2B36C10F-9800-4199-830B-5D7532E6F238

Q34158675-34D75C8B-C5CE-4400-85AB-866984D355F8

P304

Q34158675-039A2A7A-EC57-4DAE-8F38-D05EB4A00914

P31

Q34158675-965A7E60-D5BE-46AA-8D89-409CEBBB4333

P356

Q34158675-8532BAD7-141C-4B3F-981D-31347980693B

P433

Q34158675-EBAC5304-7411-4B21-9FE3-1242ED6EBCFF

P478

Q34158675-02565EB2-8F22-4ED9-A9CB-230CC505EFE0

P50

Q34158675-4337F6AD-AD74-4342-90ED-53337C8FDCD0

P577

Q34158675-24553AF8-FC98-4D5A-B731-8B77FCC40633

P5875

Q34158675-D08E533F-82C0-442D-B145-739F7B797FFD

P698

Q34158675-45DE0320-1F16-49AF-9740-2B50B97EE9E2

P932

Q34158675-0B1FB45A-9454-4592-948C-EEE06C905EB2

P356

J.DRUGALCDEP.2010.05.010

P1433

Drug and Alcohol Dependence

P1476

Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults

@en

P2093

Antoine B Douaihy

http://www.w3.org/2001/XMLSchema#string

D Scott Wood

http://www.w3.org/2001/XMLSchema#string

Dennis C Daley

http://www.w3.org/2001/XMLSchema#string

Duncan B Clark

http://www.w3.org/2001/XMLSchema#string

Jack R Cornelius

http://www.w3.org/2001/XMLSchema#string

Oscar G Bukstein

http://www.w3.org/2001/XMLSchema#string

Sandra J Brown

http://www.w3.org/2001/XMLSchema#string

P2860

A rating scale for depression

Antidepressant drug effects and depression severity: a patient-level meta-analysis

An Inventory for Measuring Depression

Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study

Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data

Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents.

Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.

Marijuana use and the risk of Major Depressive Episode. Epidemiological evidence from the United States National Comorbidity Survey.

Changing the focus: the case for recognizing and treating cannabis use disorders.

Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis.

P304

39-45

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.DRUGALCDEP.2010.05.010

http://www.w3.org/2001/XMLSchema#string

P433

1-2

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-06-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44798432

http://www.w3.org/2001/XMLSchema#string

P698

20576364

http://www.w3.org/2001/XMLSchema#string

P932

2946416

http://www.w3.org/2001/XMLSchema#string